All medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. Please consult your physician for personalized medical advice. The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional it is not intended to constitute medical advice.
FASTTRACK SCHEDULE 2017 CODE
Mechanisms of axonal injury in experimental glaucomaĮxperimental models to study trabecular meshwork pathologyĬross-talk between glaucoma pathogenic signaling pathways in the TMīrightFocus is a tax-exempt nonprofit organization under section 501(c)(3) of the Internal Revenue Code of the United States.Ĭopyright 2000 - 2020 BrightFocus Foundation. Non-rodent models of glaucomatous optic nerve damage Inducible rodent models of glaucomatous optic nerve damage New OCT developments and application to experimental glaucomaīiomechanics of outflow dysfunction in glaucoma OCT in the diagnosis and management of glaucoma Glaucoma Therapeutics in the Pipeline and the Future John Morrison, MD, Oregon Health and Science UniversityĮpidemiology and Public Health Impact of Glaucoma Preeti Subramanian, PhD, BrightFocus Foundation Introduction of BrightFocus Glaucoma Fast Track List of topics and speakers for 2022 Glaucoma Fast Track TIME (On mobile devices, you may need to swipe left to see all of the table columns below.) connecting with preeminent glaucoma experts and fellow early-stage researchers based in the U.S.immersing themselves in the background knowledge and latest discoveries in glaucoma research.Graduate students, postdoctoral fellows, or other early-stage scientists focused on glaucoma research, or those who want to enter the field, took advantage of this unique opportunity to accelerate their path towards becoming an expert in this exciting field by:
0 kommentar(er)
